成都先导终止买海纳医药 股价最深跌7.88%收盘跌1%

Core Viewpoint - Chengdu Xian Dao (688222.SH) announced the termination of a major asset restructuring plan due to the inability to reach consensus on key terms with the transaction parties, which included transaction scheme, pricing, and performance commitments [1][2]. Group 1: Termination of Major Asset Restructuring - The company disclosed that it had been actively organizing the transaction since establishing the intent with the counterparties, but failed to agree on core terms [2]. - The decision to terminate the transaction was made to protect the interests of the company and all shareholders after thorough consideration and friendly negotiations with the counterparties [2]. Group 2: Company Background and Financials - Chengdu Xian Dao was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 16, 2020, with an issuance of 40.68 million shares at a price of 20.52 yuan per share [2]. - The total funds raised from the initial public offering amounted to 834.75 million yuan, with a net amount of 746.01 million yuan after deducting issuance costs, exceeding the original plan by 85.98 million yuan [2]. - The funds were intended for projects related to new molecular design and drug research center construction [2]. Group 3: Shareholding Structure - The controlling shareholder and actual controller of the company is Jin Li, who holds British nationality [3].